NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
Clinical Trials
33 trialsNCT05806814 2026-03-05
OU-SCC-EXCITE
University of Oklahoma
Phase 1 Recruiting
NCT07219147 2026-01-28
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
City of Hope Medical Center
Phase 1 Recruiting
NCT06100705 2025-11-04
Sipuleucel-T Combined With Bipolar Androgen Therapy in Men With mCRPC
Yale University
Phase 2 Recruiting
NCT06134232 2025-08-27
ProvONE
Dendreon
Phase 2 Recruiting
NCT03686683 2024-10-08
ProVent
Dendreon
Phase 3 Completed
NCT02159950 2023-04-27
Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Roswell Park Cancer Institute
Phase 2 Completed
NCT01818986 2022-05-06
Sipuleucel-T and Stereotactic Ablative Body Radiation (SABR) for Metastatic Castrate-resistant Prostate Cancer (mCRPC)
University of Texas Southwestern Medical Center
Phase 2 Completed
NCT01804465 2021-08-18
Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate Cancer
University of California, San Francisco
Phase 2 Completed
NCT01706458 2021-06-18
Provenge With or Without pTVG-HP DNA Booster Vaccine in Prostate Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT03024216 2021-05-26
Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer
University of Hawaii
Phase 1 Completed
NCT02353715 2020-12-24
PEAX
Duke University
Completed
NCT01807065 2020-08-25
Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
City of Hope Medical Center
Phase 2 Completed
NCT01560923 2020-04-03
Phase II Study of Sipuleucel-T and Indoximod for Patients With Refractory Metastatic Prostate Cancer
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT02036918 2020-03-31
Dendreon Lymph Node Biopsy in Metastatic Castrate-Resistant Prostate Cancer
Duke University
Phase 1 Completed
NCT01727154 2019-08-19
PRIME
Dendreon
Terminated
NCT01420965 2019-07-10
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer
Augusta University
Phase 2 Terminated
NCT01306890 2019-06-07
PROCEED
Dendreon
Completed
NCT01487863 2019-03-19
Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT02232230 2019-01-09
A Multicenter Trial Enrolling Men With Advanced Prostate Cancer Who Are to Receive Combination Radiation and Sipuleucel-T
GenesisCare USA
Completed
NCT01981122 2018-10-24
A Study of Sipuleucel-T With Administration of Enzalutamide in Men With Metastatic Castrate-Resistant Prostate Cancer
Dendreon
Phase 2 Completed
NCT00779402 2018-01-29
PROTECT
Dendreon
Phase 3 Completed
NCT02793765 2017-10-30
Docetaxel Followed by Provenge in Metastatic Prostate Cancer
The University of Texas Health Science Center, Houston
Phase 2 Withdrawn
NCT01832870 2017-08-24
Sipuleucel-T and Ipilimumab for Advanced Prostate Cancer
Prostate Oncology Specialists, Inc.
Phase 1 Completed
NCT01338012 2017-06-05
mCRPC
Dendreon
Phase 2 Terminated
NCT01431391 2017-05-30
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Phase 2 Completed
NCT00715078 2017-05-23
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
Dendreon
Phase 2 Completed
NCT01477749 2015-12-09
Sipuleucel-T Manufacturing Demonstration Study
Dendreon
Phase 2 Completed
NCT00715104 2015-05-04
NeoACT
Dendreon
Phase 2 Completed
NCT00027599 2013-02-11
APC8015 and Bevacizumab in Treating Patients With Prostate Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00005947 2010-11-01
Vaccine Therapy in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Hormone Therapy
Dendreon
Phase 3 Completed
NCT01133704 2010-09-08
Immunotherapy With APC8015 (Sipuleucel-T, Provenge) for Asymptomatic, Metastatic, Hormone-Refractory Prostate Cancer
Dendreon
Phase 3 Completed
NCT00065442 2010-09-06
ProvengeĀ® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Dendreon
Phase 3 Completed